Ty comments

Posted in: China's first vaccine hustled to market as race to inoculate 1.3 bil speeds up See in context

Every western covid-19 vaccine available right now are under "emergency" approval for use only. There are obvious risks. However these have been assessed and the benefits have outweighed the risks given the huge amount of infections and deaths, especially in the US and Europe. It is a matter of getting enough data to assess the risks.

The technology used by the Pfizer-BioNTech and Moderna vaccines (mRNA) have never been used to vaccinate the public before. It usually takes years to develop a vaccine and these has been approved in about 10 months.

New technology x Limited time for development = High Risk. I would rate it as extreme.

Remember the Swine flu H1N1 vaccination debacle in 1976 in the US? A vaccine was rushed out and some people who came down with Guillain-Barre syndrome, a rare neurological disorder, after getting the 1976 flu shot. So there are long term unknown dangers with any vaccines if not enough tests and time has been allowed.

The fact that China reported that they already had "millions" vaccinated allows them to have this "necessary data" to assess the risks. So in terms of vaccine safety, they already have "more" data than the West to assess their vaccine. What they don't have is "time"; the West is in the same boat.

As for the effectiveness, I think the author is confused with effective vs efficacy. There is a difference. You can not just mixed the two word. Just search it.

It was reported that Sinopharm had a 79.34 percent effectiveness (86% effective by the UAE). I believed that it had a 100% efficacy rate.

CoronaVac reported that its vaccine was 91.25% effective are reported in Turkey.

I don't know whether these figures are true; and I think the reporter should point this out.

However, I am against mixing the two terms as it distorted the fact.

0 ( +0 / -0 )

Recent Comments

Popular

Articles, Offers & Useful Resources

A mix of what's trending on our other sites


©2024 GPlusMedia Inc.